The hepatitis therapeutics market is projected to register a CAGR of 3.5% during the forecast period.
The COVID‐19 impact on healthcare resources has adversely affected the delivery of care and outcomes of patients with chronic disease. Therefore, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease and hepatitis, which had negative consequences in the overall healthcare industry. Additionally, the clinical trials of drugs have been slow down as most companies have delayed the start for most of the new studies in several countries. Moreover, the COVID-19 pandemic has observed a decrease in outpatient services by patients with chronic hepatitis, which further highly impacted the overall market growth.
The market may show rapid growth due to the increasing prevalence of viral hepatitis, favorable government support for creating awareness about hepatitis, and the increasing availability of technologically advanced therapeutic products.
Hepatitis is an inflammation or swelling of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver, which can be fatal.
Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exams, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.
According to the World Health Organization (WHO) 2020, globally, 325 million people are estimated to be infected with hepatitis B or C. According to WHO, in 2019, Hepatitis B prevalence is highest in the WHO Western Pacific region and the WHO African region, where 6.2% and 6.1% of the adult population is infected, respectively.
Moreover, in Europe, Hepatitis B and C affect millions of people. According to the World Health Organization 2019, Hepatitis B is an infectious disease that affected around 15 million population in the WHO European region. Moreover, Hepatitis C, which is a liver disease, affected around 14 million in the European region.
Furthermore, according to the US Department of Health & Human Services, in 2018, most adults in their 20s and 30s made up 36.5% of newly reported chronic hepatitis C infections in the United States, and this is expected to increase in the forecast period.
An increase in the prevalence of viral hepatitis, a promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients to adopt hepatitis drugs are key driving factors in the hepatitis therapeutics market.
Key Market Trends
Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market
Since the COVID-19 outbreak, the market has been negatively impacted due to the supply chain and market disruption and its financial impact on firms and financial markets. The pandemic has negatively impacted the pharmaceutical industry in terms of the supply and demand for different drugs. Similarly, it is also expected to impact the overall growth of the global hepatitis market.
Hepatitis C is a liver infection that is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first six months after the individual is exposed to the hepatitis C virus, and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.
According to the World Health Organization (WHO) 2020, hepatitis C virus (HCV) infection affects over 71 million people globally. According to the same source, the hepatitis C virus is a bloodborne virus, and the common mode of infection is through exposure to small quantities of blood. This usually happens with unsafe injection practices and unsafe healthcare.
The hepatitis C segment holds a significant market share in the hepatitis therapeutics market. It is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions, and the growing availability of effective drug regimens in the market.
Moreover, several product launches by the major players are boosting the segment growth. For example, in 2019, the US Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets for the treatment of six genotypes of hepatitis C virus (HCV) in children aged between 12 and 17 years. Furthermore, in 2018, the company Natco Pharma launched a fixed-dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C in India
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The COVID-19 pandemic highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs to meet future health crises. In addition, the United States is the most COVID-affected country across the world. The supply chain of products was highly impacted in this country. Initially, the decline in diagnostic and therapeutic procedures has affected the market growth. However, as the restrictions ease, the demand for hepatitis therapeutic will significantly rise and thus drives the overall market growth in the forecast period.
North America is expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis, and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC) 2018, estimates about 2.4 million people are living with hepatitis C in the United States, and approximately 850,000 people in this region are estimated to be living with hepatitis B. In addition to the same source, 67% of persons infected with the hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advanced therapeutics, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
Furthermore, the presence of the key market players, coupled with growing awareness programs, recent products launch in the region is anticipated to boost the growth of the market in the United States. For instance, in December 2019, a new strategic plan was initiated in the United States by the National Institutes of Health outlines to intensify ongoing HBV research with the goals of developing a cure and improving scientific understanding of the virus while creating improved strategies for screening and treating patients.
The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla Inc.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Prevalence of Viral Hepatitis
4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 Poor Reimbursement Policies
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Hepatitis A
5.1.2 Hepatitis B
5.1.3 Hepatitis C
5.1.4 Hepatitis D
5.1.5 Other Types
5.2 By Drug Class
5.2.2 Monoclonal Antibody
5.2.3 Non-structural protein 5A (NS5A) Inhibitors
5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
5.2.6 Multi Class Combination
5.3 By Geography
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
5.3.3 Asia Pacific
18.104.22.168 South Korea
22.214.171.124 Rest of Asia Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6.1.1 Merck & Co. Inc.
6.1.2 Gilead Sciences Inc.
6.1.3 AbbVie Inc.
6.1.4 Bristol Myers Squibb Company
6.1.5 F Hoffmann-La Roche, Ltd
6.1.6 LAURUS Labs
6.1.7 Zydus Cadila
6.1.8 Hetero Healthcare Limited
6.1.9 NATCO Pharma Limited
6.1.10 Cipla Inc.
6.1.11 Johnson & Johnson
A selection of companies mentioned in this report includes:
- Merck & Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- F Hoffmann-La Roche, Ltd
- LAURUS Labs
- Zydus Cadila
- Hetero Healthcare Limited
- NATCO Pharma Limited
- Cipla Inc.
- Johnson & Johnson